Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict ...

In return for the ex-China rights to its new addition, called velinotamig, Cullinan has agreed to pay Genrix Bio the upfront ...

A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is ...

TegMine has identified Taiwan’s OBI as a company that can help advance its ambitions. The new deal secures TegMine the right ...

The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

Protara, hoping to ultimately transition to a commercial stage company, snagged a chief commercial officer in Bill Conkling, ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

The FDA may be facing a 4% cut to its overall budget courtesy of the Trump administration, but that hasn’t stopped the agency ...